Hanover Insurance Group (THG) Misses Q3 EPS by 89c
Get Alerts THG Hot Sheet
Price: $213.99 -0.16%
EPS Growth %: -10.8%
Financial Fact:
Gain (loss) from discontinued operations: 0
Today's EPS Names:
CCEL, FEIM, PLG, More
EPS Growth %: -10.8%
Financial Fact:
Gain (loss) from discontinued operations: 0
Today's EPS Names:
CCEL, FEIM, PLG, More
Join SI Premium – FREE
Hanover Insurance Group (NYSE: THG) reported Q3 operating EPS of $0.99, $0.89 worse than the analyst estimate of $1.88.
- Combined ratio of 101.0%; combined ratio, excluding catastrophes(1), of 94.2%
- Catastrophe losses of $90.1 million, or 6.8 points of the combined ratio, including the impact from Hurricane Ian of $28.0 million
- Net premiums written increase of 9.5%*, with contributions from each segment
- Renewal price change(2) of 11.2% in Core Commercial, 12.4% in Specialty and 7.3% in Personal Lines, driven by homeowners renewal price change of 12.1%
- Rate increases(2) of 7.3% in Core Commercial, 8.0% in Specialty and 4.0% in Personal Lines
- Current accident year loss and loss adjustment expense (\"LAE\") ratio, excluding catastrophes(3), of 64.1% reflecting higher-than-expected inflation, primarily impacting personal auto, homeowners, and commercial multiple peril (\"CMP\") property lines, as well as property large loss activity in CMP
- Net investment income of $73.0 million, above expectations and helped by higher operational cashflows and bond reinvestment rates, but below the prior-year quarter result due to the elevated level of partnership income in the third quarter of 2021
- Book value per share of $64.59, down 10.5% from June 30, 2022, primarily driven by a decrease in the fair value of fixed maturity investments due to the higher interest rate environment
For earnings history and earnings-related data on Hanover Insurance Group (THG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
- Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
- FDA approves Padcev plus Keytruda for muscle-invasive bladder cancer
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share